The PI3K/AKT signaling networks in cancer glucose metabolism: mechanisms and therapeutic implications Authors: Sufen Cheng, Qi Jiang, Hua Huang, Hongyan Tong, Mixue Xie Published: 2026 ABSTRACT Highlights•Focuses on the PI3K/AKT axis– its core link to cancer metabolic reprogramming (especially the Warburg Effect) and interaction with key glucose metabolic enzymes (HK, LDHA, etc.), as well as their impacts.•2. Introduces the non-canonical/moonlighting functions of these glucose metabolic enzymes.•3. Provides theoretical basis and potential targets for tumor metabolism research and targeted therapy, along with current research challenges and future directions. Introduction Metabolic reprogramming is a hallmark of cancer, underpinning the rapid proliferation and survival of cancer cells. A cornerstone of this phenomenon is the Warburg effect, where tumor cells predominantly rely on glycolysis for energy even in the presence of oxygen, supports rapid cell proliferation by generating ATP and providing intermediates for biosynthesis processes, such as protein, lipid and nucleotide synthesis [1,2]. This reprogrammed glycolytic phenotype is orchestrated by multiple oncogenic pathways, among which the PI3K/AKT axis represents one of the most potent and commonly activated drivers. Abnormal activation of the PI3K/AKT axis is common in cancer and plays a crucial role in this metabolic shift [3]. The PI3K/AKT axis regulates a broad array of metabolic pathways, including glycolysis, the pentose phosphate pathway (PPP), oxidative phosphorylation (OXPHOS), de novo lipogenesis, all of which contribute to tumor cell energy demands [4]. Aberrant activation of this pathway has been implicated in various aspects of cancer biology, such as enhanced glucose uptake, increased glycolytic flux, and altered redox homeostasis. However, the mechanisms by which PI3K/AKT influences key metabolic enzymes remain incompletely understood, particularly with respect to its direct regulation of glycolytic enzymes and the emerging non-canonical functions of these enzymes in tumor. This review provides a comprehensive analysis of the PI3K/AKT pathway’s role in cancer metabolism. It focuses on the direct regulation of key glycolytic enzymes (hexokinase (HK), pyruvate kinase (PK), phosphofructokinase (PFK), aldolase, and lactate dehydrogenase (LDH)), emphasizing the PI3K/AKT pathway’s contributions to the Warburg effect and metabolic plasticity. We also discuss the interplay between PPP, OXPHOS, de novo lipogenesis, and the therapeutic potential of targeting these metabolic pathways in cancer, which provides a theoretical basis for prognostic stratification and combined targeted therapy. Additionally, we conclude the challenges of targeting PI3K/AKT-mediated metabolic reprogramming, including metabolic heterogeneity, compensatory adaptations, and drug toxicity. Finally, we propose future directions for precision metabolic targeting and combination strategies to overcome therapeutic barriers. This review offers a framework for understanding PI3K/AKT signaling in cancer metabolism and highlights new therapeutic opportunities. Mechanisms of PI3K/AKT pathway in regulating cancer glucose metabolism The composition and activation mechanisms of the PI3K/AKT pathway The PI3K/AKT axis is a central signaling pathway critically involved in regulating cell growth, survival, and metabolism. PI3K, a lipid kinase typically comprising a p110 catalytic subunit and p85/p55 regulatory subunits, is frequently dysregulated in human diseases, especially in cancer [3]. Based on structure and substrate specificity, PI3K can be categorized into three classes. Class I PI3Ks, the primary transducers of extracellular signals, are the most studied [3]. Activation of this pathway is triggered by various signals, including growth factors (e.g., EGF, IGF), cytokines (e.g., IL-6), hormones, and oncogene activation (e.g., RAS, MYC) (Fig. 1) [4]. These ligands bind to cell-surface receptor tyrosine kinases (RTKs), such as EGFR, IGF-1R, or cytokine receptors, to initiate downstream signaling cascades. Upon activation, PI3K converts phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 recruits AKT to the plasma membrane, where it is partially activated by phosphorylation at Thr308 by phosphoinositide-dependent kinase 1 (PDK1) and fully activated at Ser473 by mechanistic target of rapamycin complex 2 (mTORC2) [3]. This signaling cascade is negatively regulated by the tumor suppressor PTEN, which dephosphorylates PIP3 back to PIP2. In addition to PTEN-mediated repression, AKT activity is tightly controlled by serine/threonine phosphatase 2A (PP2A). The PP2A regulatory subunit PR130 (encoded by PPP2R3A) is essential for assembling functional holoenzymes that restrain AKT signaling [5,6]. PP2A directly dephosphorylates AKT at Thr308 and Ser473, thereby suppressing downstream signaling [7]. Loss of PR130 disrupts PP2A-AKT binding and sustains AKT hyperactivation [5,6]. In hepatocellular carcinoma, aldolase B stabilizes the PP2A-AKT complex to further promote AKT dephosphorylation, underscoring PR130 as a key negative regulator of oncogenic AKT signaling [7]. AKT1 and AKT2 exhibit widespread tissue expression. AKT is a serine/threonine protein kinase critically involved in cancer metabolic reprogramming. The AKT family contains three functionally distinct subtypes: AKT1, AKT2 and AKT3. AKT1 is ubiquitously activated in diverse tumors; GPR75/20-HETE signaling triggers AKT1 phosphorylation and activation, subsequently activating NF-κB to upregulate HK2 and glucose transporter 1 (GLUT1), thereby enhancing tumor glucose uptake [[8], [9], [10]]. Additionally, AKT1 activates mTORC1 to promote protein and lipid biosynthesis, supporting tumor proliferation by rewiring glucose metabolism [[11], [12], [13]]. Notably, AKT2 plays a key role in insulin-sensitive metabolic tissues. It can promote the translocation of GLUT4 to the cell membrane, increasing glucose uptake. Moreover, AKT2 directly drives glycolysis by phosphorylating tumor-associated 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3/4 (PFKFB3/PFKFB4) to accelerate glycolytic flux. In contrast, AKT3 displays a more tissue-restricted pattern, with predominant expression in the brain [4]. Under hypoxia, AKT3 stabilizes and promotes nuclear translocation of HIF-1α, inducing glycolytic genes including GLUT1, HK2, and LDHA [14,15]. AKT3 also modulates lipid-glucose metabolic crosstalk and indirectly activates c-Myc to reinforce tumor glycolysis [15]. Once activated, AKT exerts profound control over cancer glucose metabolism through a multifaceted network. This includes the direct phosphorylation and regulation of key glycolytic enzymes such as HK2 and PKM2, coupled with the inactivation of tumor suppressors (e.g., GSK3, FOXO, and BAD) and the activation of master anabolic regulators (e.g., mTORC1, MYC, HIF-1α) [3,4]. Beyond its canonical lipid kinase activity, PI3K also exerts non-canonical, PIP3-independent functions. Recent evidence in glioblastoma has uncovered that the p110β catalytic subunit possesses intrinsic serine/threonine kinase activity. Under high-glucose conditions, PI3K signaling, potentially involving p110β, enhances global protein O-GlcNAcylation, likely through the activation of O-GlcNAc transferase [16]. This modification subsequently activates ATP-citrate lyase (ACLY), promoting de novo fatty acid synthesis and supporting tumor growth. This PIP3/AKT-independent pathway, together with the established regulation of non-metabolic enzyme functions (e.g., AKT-mediated nuclear translocation of PKM2), demonstrates that the PI3K/AKT axis transcends traditional signaling paradigms [17].Fig. 1Overview of the PI3K/AKT Signaling Cascade. Growth factors, cytokines and hormones bind to receptor tyrosine kinases (RTKs), whereas oncogenic activation directly triggers PI3K signaling to initiate downstream AKT activation. Upon activation, AKT upregulates oncogenic mediators and metabolic regulators including mTORC1, HIF-1α, ACLY, and c-Myc, while repressing tumor-suppressive factors FOXO, GSK3, and BAD. These downstream events collectively induce core cancer phenotypes: anti-apoptosis, metastasis, proliferation, stemness, and angiogenesis under hypoxic conditions.Fig 1 dummy alt text Overview of the PI3K/AKT Signaling Cascade. Growth factors, cytokines and hormones bind to receptor tyrosine kinases (RTKs), whereas oncogenic activation directly triggers PI3K signaling to initiate downstream AKT activation. Upon activation, AKT upregulates oncogenic mediators and metabolic regulators including mTORC1, HIF-1α, ACLY, and c-Myc, while repressing tumor-suppressive factors FOXO, GSK3, and BAD. These downstream events collectively induce core cancer phenotypes: anti-apoptosis, metastasis, proliferation, stemness, and angiogenesis under hypoxic conditions. PI3K/AKT-mediated direct regulation of glycolytic enzymes: metabolic catalysis and emerging non-metabolic roles In cancer cells, the reprogramming of glucose metabolism is executed by the precise modulation of key glycolytic enzymes. The PI3K/AKT axis sits at the apex of this regulatory network, controlling both the activity and expression of these enzymes to drive the Warburg effect. We illustrate the main steps of glucose metabolism and the regulation of the PI3K/AKT pathway (Fig. 2), and also elaborate on the non-canonical functions of these glycolytic enzymes.Fig. 2Schematic Illustration of PI3K/AKT-driven Metabolic Reprogramming in Tumor Cells. Activated PI3K/AKT signaling rewires core glucose metabolism by upregulating glycolytic enzymes (HK2, PFK, PKM2, LDHA) to trigger the Warburg effect. Mechanistically, PI3K/AKT-activated PDK1 (3-phosphoinositide-dependent protein kinase 1) suppresses PDH (pyruvate dehydrogenase) activity, restricting pyruvate flux into the TCA (tricarboxylic acid) cycle and subsequent mitochondrial OXPHOS. PI3K/AKT simultaneously promotes PPP-derived NADPH production coupled with GSH (glutathione) to maintain redox homeostasis, and drives de novo lipogenesis via ACLY- and FASN-mediated cascades to fuel cell proliferation, with metabolic crosstalk between de novo lipogenesis and the TCA cycle. ROS (reactive oxygen species) generated by dysfunctional mitochondrial ETC (electron transport chain) I-V reciprocally reactivate upstream PI3K/AKT signaling, forming a positive feedback loop. Small molecule inhibitors targeting PI3K/AKT, key glycolytic enzymes, and OXPHOS are indicated in the diagram.Fig 2 dummy alt text Schematic Illustration of PI3K/AKT-driven Metabolic Reprogramming in Tumor Cells. Activated PI3K/AKT signaling rewires core glucose metabolism by upregulating glycolytic enzymes (HK2, PFK, PKM2, LDHA) to trigger the Warburg effect. Mechanistically, PI3K/AKT-activated PDK1 (3-phosphoinositide-dependent protein kinase 1) suppresses PDH (pyruvate dehydrogenase) activity, restricting pyruvate flux into the TCA (tricarboxylic acid) cycle and subsequent mitochondrial OXPHOS. PI3K/AKT simultaneously promotes PPP-derived NADPH production coupled with GSH (glutathione) to maintain redox homeostasis, and drives de novo lipogenesis via ACLY- and FASN-mediated cascades to fuel cell proliferation, with metabolic crosstalk between de novo lipogenesis and the TCA cycle. ROS (reactive oxygen species) generated by dysfunctional mitochondrial ETC (electron transport chain) I-V reciprocally reactivate upstream PI3K/AKT signaling, forming a positive feedback loop. Small molecule inhibitors targeting PI3K/AKT, key glycolytic enzymes, and OXPHOS are indicated in the diagram. Hexokinase: PI3K/AKT regulation and moonlighting functions HK is the first rate-limiting enzyme in glycolysis, catalyzing the phosphorylation of glucose to produce glucose-6-phosphate, thereby trapping glucose inside the cell and initiating glycolytic flux. Accumulating evidence confirms a direct correlation between tumor cell growth rate and HK activity [18]. Among the four HK isoforms (HK1 to HK4), HK2 is of particular importance in cancer. HK2, which consists of two catalytically active N- and C-terminal lobes and is feedback-inhibited by glucose-6-phosphate, is frequently overexpressed in malignancies such as colorectal, breast, pancreatic, and cervical cancer [3,19]. Its overexpression correlates with poor prognosis, therapeutic resistance, and serves as a key driver of the Warburg effect. The PI3K/AKT axis regulates HK2 via interconnected mechanisms that enhance its expression, stability, and catalytic efficiency. It transcriptionally upregulates HK2 via downstream effectors like HIF-1α and c-Myc, which directly bind to the HK2 promoter [15]. Additionally, context-specific activation of distinct AKT isoforms fine-tunes HK2 levels. For example, in certain cancer types, AKT1 activation via the GPCR75/20-HETE axis triggers NF-κB-mediated upregulation of HK2 [10,20]. More distinctively, AKT promotes the mitochondrial translocation of HK2, facilitating its binding to voltage-dependent anion channel (VDAC), which facilitates access to mitochondrially-derived ATP for glycolysis while concurrently inhibiting apoptosis by stabilizing the mitochondrial membrane [21]. This AKT/HK2 axis is subject to precise feedback regulation. The phosphatase PHLPP can dephosphorylate AKT and promote HK2 translocation from mitochondria to the cytosol, forming a complex regulatory circuit that matches HK2 activity to the metabolic state of the cell [22]. Beyond its canonical role in glycolysis, HK2 exhibits non-metabolic ("moonlighting") functions that are also influenced by PI3K/AKT signaling. A significant pool of HK2 localizes to mitochondria-associated membranes, where its AKT-mediated phosphorylation at Thr473 stabilizes the IP3R-GRP75-VDAC1 complex, facilitating pro-survival Ca²⁺ signaling to mitochondria [23]. Displacement of phosphorylated HK2 disrupts this Ca²⁺ flux, inducing cell death and highlighting this process as a therapeutic vulnerability [23]. Furthermore, under hypoxic stress, the interaction between mitochondrial HK2 and TP53-induced glycolysis and apoptosis regulator not only boosts HK2 activity but also mitigates reactive oxygen species accumulation, offering an additional layer of protection to cancer cells [3]. Phosphofructokinase (PFK): AKT-mediated regulation via PFKFB isoforms PFK-1 serves as a critical rate-limiting enzyme in glycolysis, catalyzing the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. Its activitiy is tightly regulated by fructose-2,6-bisphosphate (F-2,6-BP), a potent allosteric activator synthesized by the bifunctional enzyme family 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1–4). Among these isoforms, PFKFB3 and PFKFB4 are highly expressed in tumor and function as key modulators of glycolytic flux through the control of intracellular F-2,6-BP levels [24]. AKT phosphorylates and activates specific PFKFB isoforms, particularly PFKFB3 and PFKFB4, leading to an increase in cellular F-2,6-BP levels, which subsequently activates PFK-1 and promotes glycolysis [25]. Additionally, transcriptional regulation further links AKT signaling to PFK expression. Activated AKT upregulates transcription factors c-Myc and HIF-1α via mTORC1, which directly bind to the promoter regions of PFKFB3 and PFK1 to promote their transcription [26]. This synergistic regulation is evident in kidney cancer cells, where PI3K/AKT/mTORC1 pathway activation increases c-Myc and HIF-1α levels, thereby upregulating PFKFB3 mRNA and protein expression [27]. Moreover, AKT regulates PFK activity through nuclear-cytoplasmic shuttling of PFKFB3, suggesting a spatial mechanism for fine-tuning PFK activity [28]. Functionally, PFKFB3 displays high kinase activity, efficiently generating F-2,6-BP to sustain glycolytic flux, whereas PFKFB4 may coordinate the redistribution of metabolites toward the PPP to support redox balance and biosynthesis [29]. Interestingly, PFKFB4 can also enhance AKT signaling by modulating the histone acetyltransferase GCN5 or interacting with isoprenylcystein carboxyl methyl transferase, establishing a reciprocal regulatory loop between glycolytic enzymes and oncogenic signaling [30,31] Pyruvate kinase (PK): PI3K/AKT-modulated dual functions PK, the terminal enzyme of glycolysis, catalyzes the conversion of phosphoenolpyruvate to pyruvate and ATP. PK subtypes include PKM1, PKM2, PKL, and PKR. PKM1 and PKM2 are transcribed from the PKM gene via alternative splicing. Notably, PKM2 contains its unique exon 10 but lacks exon 9, which is specific to PKM1 and highly expressed in embryonic tissues, stem cells, and tumor cells. This difference in this single exon leads to an important functional distinction. A shift from PKM1 to PKM2 expression is observed in various cancers, and reversing this shift inhibits aerobic glycolysis and tumorigenesis in xenograft models [32]. PKM2’s abnormal expression correlates with poor prognosis in digestive system solid tumors, and its activity is regulated by metabolites, phosphorylation, and oligomeric state [33]. The PI3K/AKT pathway plays a key role in PKM2 regulation: It maintains PKM2 in a low-activity dimeric state through phosphorylation, diverting glycolytic intermediates toward biomass synthesis to support tumor proliferation and the Warburg effect [33,34]. PKM2 can also switch to a highly active tetrameric form (e.g., induced by metabolites like F-1,6-BP) to generate ATP, adapting to cellular energy demands. Beyond downstream regulation by PI3K/AKT, PKM2 also functions as an upstream regulator of the pathway, forming a bidirectional regulatory loop [33]. Beyond its metabolic role, PKM2 exhibits pivotal non-metabolic ("moonlighting") functions. As a protein kinase and transcriptional co-activator, PKM2 binds to histone H3 and interacts with transcription factors like HIF-1α and β-catenin to promote the expression of glycolysis-related genes through epigenetic regulation [35]. Of note, PKM2 exhibits non-canonical "moonlighting" functions in immune modulation. Extracellular PKM2 from tumor cells binds macrophage integrin αvβ3, activating the integrin/FAK/PI3K axis [36]. This signaling suppresses PTEN expression, upregulates arginase 1, and drives M2 polarization, fostering an immunosuppressive microenvironment. Aldolase and lactate dehydrogenase (LDHA): roles in PI3K/AKT signaling networks Aldolase catalyzes the cleavage of F-1,6-BP to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate, with its activity influencing glycolytic rate and correlating with poor tumor prognosis. Beyond its canonical metabolic functions, aldolase exhibits diverse non-canonical roles. Notably, in pancreatic cancer, aldolase undergoes K11- and K29-linked ubiquitination, which facilitates its nuclear translocation [37]. In hepatocellular carcinoma cells, aldolase B binds to AKT via specific structural domains and recruits protein phosphatase PP2A, which dephosphorylates AKT at Ser473, inhibiting AKT activity [7]. Furthermore, aldolase A binds to F-actin in a non-enzymatic manner, which decreases its enzymatic activity while promoting tumor cell migration and invasion [38]. Glucose deprivation decreases the aldolase substrate F-1,6-BP, which in turn mediates aldolase dissociation from F-actin. The liberated enzyme then interacts with and activates the class II PI3K isoform PI3KC2α, initiating adaptive signaling pathways to counteract metabolic stress [4]. LDHA catalyzes the conversion of pyruvate to lactate, the final step in glycolysis. Studies have shown that after knocking down LDHA, glucose uptake and lactate production are significantly reduced [39]. LDHA levels are elevated in pancreatic cancer, nasopharyngeal carcinoma, stomach cancer, bladder cancer, and endometrial carcinoma, closely linked to PI3K/AKT overactivation [3]. AKT activate the transcription of HIF-1α and c-Myc, upregulating LDHA expression [9]. In turn, the lactate can up-regulate the phosphorylation level of AKT by indirectly activating PI3K (with ATP derived from glycolysis), forming a self-reinforcing loop [40]. Lactate accumulation in the tumor microenvironment induces local acidosis, inhibiting immune cell function and facilitating tumor immune escape, migration, and metastasis [[41], [42], [43]]. Other signaling pathways interacting with the PI3K/AKT pathway The PI3K/AKT signaling axis acts as a significant regulator of energy metabolism and redox homeostasis, exerting dual effects on the AMPK energy-sensing pathway and multiple glycolysis-associated metabolic pathways. By engaging in reciprocal regulatory crosstalk with AMPK, PI3K/AKT fine-tunes the balance between anabolic and catabolic processes to meet the metabolic demands of cells. Meanwhile, PI3K/AKT modulates PPP, OXPHOS, and de novo lipogenesis—key branches interconnected with glycolysis—to orchestrate metabolic networks that support cell proliferation, survival, and malignant progression. Crosstalk with AMPK: reciprocal regulation between PI3K/AKT axis and energy sensor AMP-activated protein kinase (AMPK) serves as a cellular energy receptor that is activated upon elevation of the AMP/ATP ratio. AMPK, activated under energy shortage and suppressed in its surfeit, inversely regulates glycolysis in accordance with cellular metabolic status. When nutrients are abundant, AMPK attenuates aerobic glycolysis to restrain unnecessary anabolic processes. Conversely, under metabolic stress—particularly glucose scarcity—AMPK shifts its function to promote glycolysis, thereby sustaining ATP production and ensuring short-term cell viability. Activation of the PI3K/AKT axis typically suppresses AMPK activity through multiple mechanisms, including phosphorylating inhibitory sites of AMPK or downregulating upstream kinases of AMPK like LKB1. This inhibition relieves AMPK-mediated suppression of mTORC1 and aerobic glycolysis, allowing tumor cells to maintain a high level of anabolism and support their rapid proliferation and energy demands [44,45]. Consistent with this, studies have found that the deletion of PRKAA1/2 (AMPKα-encoding gene) can lead to an increase in the mRNA expression of ALDOA, LDHA and PDK1, which all indicate that AMPK negatively regulates the glycolysis process of tumor cells and inhibits tumor growth [46]. Notably, AMPK can exert feedback regulation on AKT, forming a mutually restrictive balance. Activated AMPK inhibits AKT activity primarily by phosphorylating its inhibitory sites (Ser485) Or inhibiting the activity of mTORC2 [47]. In addition, AMPK also regulates non-metabolic processes, such as the progression of the cell cycle and the excitability of neuronal membranes, with the aim of protecting ATP [47]. Glycolysis-related metabolic pathways: PI3K/AKT-mediated regulation of pentose phosphate pathway, oxidative phosphorylation, and de novo lipogenesis The PPP, a key branch of glucose metabolism, uses glucose-6-phosphate as its substrate, proceeding through two stages: oxidative and non-oxidative. It not only provides key biosynthetic raw materials for cells but also participates in the maintenance of redox homeostasis. Together with pathways such as glycolysis and the tricarboxylic acid cycle, it constitutes a complex intracellular carbohydrate metabolism network. The oxidative phase generates NADPH, essential for biosynthesis, antioxidant defense, and nucleotide synthesis [48,49]. The non-oxidative phase produces intermediates like ribose-5-phosphate, a precursor for nucleotides. The PI3K/AKT pathway enhances the PPP by stabilizing Glucose-6-Phosphate Dehydrogenase (G6PD) through inhibition of the newly identified E3 ubiquitin ligase TRIM21. In turn, PPP metabolites reinforce AKT activation and further drive cancer metabolic reprogramming by repressing expression of the AKT inhibitor PHLDA3 [50]. Notably, AKT can also enhance the function of the PPP by regulating the activities of other enzymes. This regulation includes both direct actions, such as the regulation of transketolase, and indirect methods, which are achieved by promoting the transcription and translation of MYC-related phosphoribosyl pyrophosphate synthetase 2 [51]. OXPHOS is the core process of energy production within cells, generating ATP by oxidizing nutrients in the mitochondrial respiratory chain. OXPHOS is the final stage of aerobic respiration and occurs in the inner mitochondrial membrane of the cell. It includes two reactions: the oxidation reaction of the electron transport chain and the phosphorylation reaction of ATP synthase. The regulation of the PI3K/AKT axis on mitochondrial OXPHOS is relatively complex and cell-specific. In tumor cells, AKT inhibits mitochondrial OXPHOS by phosphorylating the catalytic subunit of pyruvate dehydrogenase. However, in normal cells, AKT supports mitochondrial function by activating mTORC1, which promotes mitochondrial protein synthesis and respiratory chain complex assembly. For example, in T cells, PI3K/AKT/mTOR activation supports mitochondrial biogenesis, aiding rapid proliferation and differentiation [50]. De novo lipogenesis converts non-lipid substances into fatty acids. AKT can activate the enzyme activity of ACLY through phosphorylation, initiate lipid synthesis, and promote the migration and invasion of cancer cells [52]. In cancers like ovarian and hematologic tumors, PI3K/AKT/mTOR regulates lipid synthesis by controlling ACLY and fatty acid synthase [53]. Fatty acid metabolism links with glucose metabolism, as fatty acids support glucose metabolism in tumor cells. Therefore, AKT establishes a link between lipid metabolism and glucose metabolism in tumor cells by regulating the activity of ACLY, promoting the proliferation and survival of tumor cells. Overexpression of ACLY is relatively common in various human malignancies, and ACLY inhibitors are being tested as anti-cancer therapies [54]. Targeted therapeutic strategies for PI3K/AKT-mediated metabolic reprogramming Metabolic reprogramming is a well-recognized adaptive hallmark of cancer cells, with aberrant glycolysis standing out as one of the most extensively characterized and therapeutically exploitable alterations. Targeting glycolytic enzymes and integrating these agents with other pathway-specific inhibitors or immunotherapies have emerged as promising strategies to overcome tumor cell survival advantages and drug resistance. Therapeutic targeting of metabolic enzymes in the PI3K/AKT signaling pathway Aberrant glycolytic metabolism, a hallmark of cancer, offers a fertile ground for therapeutic intervention. By targeting key enzymes that drive this metabolic reprogramming, it is possible to disrupt the energy supply and biosynthetic pathways essential for cancer growth and survival. This section summarizes the current development of agents targeting several pivotal glycolytic enzymes. (Table 1)Table 1Major glycolysis-targeted drugs in cancer.Table 1 dummy alt textDrugTarget MoleculeMechanism of ActionResearch StageKey FindingsCancerRef.2-deoxyglucoseHK2Inhibiting the activity of HKPhaseI, II trialsCombined therapy is effective, while monotherapy has high toxicityGlioblastomaBreast cancerProstate cancer[3]BenitrobenrazideHK2Inhibit glucose uptake and lactate productionIn vitro studiesHigh activity and low toxicityPancreatic cancerColorectal cancer[56]WogoninEpigallocatechin-3-gallateβ-escinTocotrienolsHK2HK2 downregulationIn vitro and in vivo studiesPhase I, II trialsHigh activity in vitro, no toxicity but modest efficacy in vivo and in patientsLiver cancerBreast cancer[68]QuercetinHK2Reduce the protein level of HK2In vitro and in vivo studiesLow bioavailabilityLiver cancer[3]Specific anti-HK2 peptidesHK2Selective removal of HK2 from outer mitochondrial membraneIn vitro studiesHigh activityGlioblastomaPancreatic cancer[35]Lonidamine 3-bromopyruvateHK2Catalytic inhibition of HK2Phase I, II and III trialsHigh clinical efficacy but severe toxicityLiver cancer[3]3PO, PQPCompound 26PFKFB3Inhibit the kinase activity of PFKFB3In vitro and in vivo studiesHigh activity but low bioavailabilityLung cancerColorectal cancer[24]KAN0438757PFKFB3Inhibit the kinase activity of PFKFB3In vitro and in vivo studiesHigh activity but lack of human pharmacokinetic dataPancreatic cancerColorectal cancer[24]Shikonin AlkanninPKM2Allosteric inhibition of PKM2In vitro studiesHigh activityLung cancerMelanoma[57,58]TEPP-46PKM2Tetrameric PKM2In vitro and in vivo studiesHigh activityLung cancer[57]DichloroacetatePDKPromote the entry of pyruvate into mitochondria for oxidationPreclinical studyPhase I, II trialsThe therapeutic effects vary greatly from person to personGlioblastomaNon-small cell lung cancerHematological tumors[69]AZD3965MCT-1Selectively inhibit MCT-1Phase I trialsHigh clinical efficacy but severe toxicityGastric cancerProstate cancerBreast cancer[70]OxamateLDHAPyruvate-competitive inhibition of LDHAIn vitro and in vivo studiesHigh activityNasopharyngeal CarcinomaGlioblastoma[3]FX11Quinoline 3-sulfonamidesLDHANADH-competitive inhibition of LDHAIn vitro and in vivo studiesHigh in vitro activity and in vivo efficacyLiver cancerPancreatic cancerBreast cancer[3]N-hydroxyindolesLDHANADH-competitive inhibitionof LDHAIn vitro studiesHigh activityLiver cancerBreast cancerHematological tumors[3]GalloflavinLDHAInhibition of LDHA functionIn vitro studiesHigh activityLiver cancerLung cancerHematological tumors[3]GNE-140LDHACompetitive inhibition of LDHAIn vitro and in vivo studiesHigh activitylymphoma[59]MatrineApigeninGenistein QuercetinresveratrolcurcuminGLUT-1GLUT-1 downregulationIn vitro and vivo studiesPhase I, II trialsHigh activity in vitro, no toxicity but modest efficacy in vivo and in patientsLiver cancerBreast cancer[68,71]BAY-876STF-31WZB117GLUT1Inhibition of GLUT-1 functionIn vitro and in vivo studiesPhase I, II trialsHigh activity in vitro, no toxicity but modest efficacy in vivoLiver cancerBreast cancer[61,64]DMeFBP6-DMeFBP 1,6-DMeFBPPGAM1Inhibit the activity of PGAM1In vitro studiesHigh activityLiver cancerLung cancer[66]Abbreviation: Hexokinase 2 (HK2); 6‑phosphofructo‑2‑kinase/fructose‑2,6‑bisphosphatase 3 (PFKFB3); Pyruvate Kinase M2 (PKM2); Pyruvate Dehydrogenase Kinase (PDK); Monocarboxylate Transporter 1 (MCT-1); Lactate Dehydrogenase A (LDHA); Glucose Transporter 1 (GLUT-1); Phosphoglycerate Mutase 1 (PGAM1). Table 1Major glycolysis-targeted drugs in cancer.Table 1 dummy alt textDrugTarget MoleculeMechanism of ActionResearch StageKey FindingsCancerRef.2-deoxyglucoseHK2Inhibiting the activity of HKPhaseI, II trialsCombined therapy is effective, while monotherapy has high toxicityGlioblastomaBreast cancerProstate cancer[3]BenitrobenrazideHK2Inhibit glucose uptake and lactate productionIn vitro studiesHigh activity and low toxicityPancreatic cancerColorectal cancer[56]WogoninEpigallocatechin-3-gallateβ-escinTocotrienolsHK2HK2 downregulationIn vitro and in vivo studiesPhase I, II trialsHigh activity in vitro, no toxicity but modest efficacy in vivo and in patientsLiver cancerBreast cancer[68]QuercetinHK2Reduce the protein level of HK2In vitro and in vivo studiesLow bioavailabilityLiver cancer[3]Specific anti-HK2 peptidesHK2Selective removal of HK2 from outer mitochondrial membraneIn vitro studiesHigh activityGlioblastomaPancreatic cancer[35]Lonidamine 3-bromopyruvateHK2Catalytic inhibition of HK2Phase I, II and III trialsHigh clinical efficacy but severe toxicityLiver cancer[3]3PO, PQPCompound 26PFKFB3Inhibit the kinase activity of PFKFB3In vitro and in vivo studiesHigh activity but low bioavailabilityLung cancerColorectal cancer[24]KAN0438757PFKFB3Inhibit the kinase activity of PFKFB3In vitro and in vivo studiesHigh activity but lack of human pharmacokinetic dataPancreatic cancerColorectal cancer[24]Shikonin AlkanninPKM2Allosteric inhibition of PKM2In vitro studiesHigh activityLung cancerMelanoma[57,58]TEPP-46PKM2Tetrameric PKM2In vitro and in vivo studiesHigh activityLung cancer[57]DichloroacetatePDKPromote the entry of pyruvate into mitochondria for oxidationPreclinical studyPhase I, II trialsThe therapeutic effects vary greatly from person to personGlioblastomaNon-small cell lung cancerHematological tumors[69]AZD3965MCT-1Selectively inhibit MCT-1Phase I trialsHigh clinical efficacy but severe toxicityGastric cancerProstate cancerBreast cancer[70]OxamateLDHAPyruvate-competitive inhibition of LDHAIn vitro and in vivo studiesHigh activityNasopharyngeal CarcinomaGlioblastoma[3]FX11Quinoline 3-sulfonamidesLDHANADH-competitive inhibition of LDHAIn vitro and in vivo studiesHigh in vitro activity and in vivo efficacyLiver cancerPancreatic cancerBreast cancer[3]N-hydroxyindolesLDHANADH-competitive inhibitionof LDHAIn vitro studiesHigh activityLiver cancerBreast cancerHematological tumors[3]GalloflavinLDHAInhibition of LDHA functionIn vitro studiesHigh activityLiver cancerLung cancerHematological tumors[3]GNE-140LDHACompetitive inhibition of LDHAIn vitro and in vivo studiesHigh activitylymphoma[59]MatrineApigeninGenistein QuercetinresveratrolcurcuminGLUT-1GLUT-1 downregulationIn vitro and vivo studiesPhase I, II trialsHigh activity in vitro, no toxicity but modest efficacy in vivo and in patientsLiver cancerBreast cancer[68,71]BAY-876STF-31WZB117GLUT1Inhibition of GLUT-1 functionIn vitro and in vivo studiesPhase I, II trialsHigh activity in vitro, no toxicity but modest efficacy in vivoLiver cancerBreast cancer[61,64]DMeFBP6-DMeFBP 1,6-DMeFBPPGAM1Inhibit the activity of PGAM1In vitro studiesHigh activityLiver cancerLung cancer[66]Abbreviation: Hexokinase 2 (HK2); 6‑phosphofructo‑2‑kinase/fructose‑2,6‑bisphosphatase 3 (PFKFB3); Pyruvate Kinase M2 (PKM2); Pyruvate Dehydrogenase Kinase (PDK); Monocarboxylate Transporter 1 (MCT-1); Lactate Dehydrogenase A (LDHA); Glucose Transporter 1 (GLUT-1); Phosphoglycerate Mutase 1 (PGAM1). Major glycolysis-targeted drugs in cancer. Abbreviation: Hexokinase 2 (HK2); 6‑phosphofructo‑2‑kinase/fructose‑2,6‑bisphosphatase 3 (PFKFB3); Pyruvate Kinase M2 (PKM2); Pyruvate Dehydrogenase Kinase (PDK); Monocarboxylate Transporter 1 (MCT-1); Lactate Dehydrogenase A (LDHA); Glucose Transporter 1 (GLUT-1); Phosphoglycerate Mutase 1 (PGAM1). HK2 represents a high-value therapeutic target in oncology, given its pivotal role in cancer metabolism. However, efforts to pharmacologically exploit this vulnerability have encountered significant bottlenecks. Early-generation inhibitors, such as 2-deoxyglucose and lonidamine, demonstrated clinical efficacy but were hampered by dose-limiting systemic toxicity and off-target effects [3]. Consequently, research has shifted towards more selective strategies. These include the development of novel small-molecule inhibitors (e.g., benitrobenrazide) and the exploration of natural compounds (e.g., thymoquinone) that can disrupt HK2’s mitochondrial localization or downregulate its expression via the AKT pathway [55,56]. Particularly promising are peptide-based strategies designed to specifically evict HK2 from the mitochondrial membrane, which have shown potent tumor-specific cytotoxicity in preclinical models by perturbing mitochondrial function and Ca²⁺ flux [23]. In parallel, the development of inhibitors targeting PFKFB3 (e.g., 3PO, PQP, and PFK-158, the latter in Phase II clinical trials with no published literature yet) has become an active therapeutic strategy [24]. Notably, targeting PKM2 with small molecules, from the direct inhibitors shikonin and alkannin to the allosteric activator TEPP-46, effectively reduces lactate production and inhibits cancer cell proliferation (Table 1) [57,58]. Lactate also serves as an energy source or biosynthetic raw material for tumor cells. The competitive inhibition of LDHA by small molecules, including modern candidates like GNE-140 and N-hydroxyindoles as well as earlier agents such as quercetin, reduces tumor lactate production and induces energy depletion, despite potential risks from interfering with healthy T cell metabolism [3,59]. more selective approaches, such as nanoparticles loaded with lactate oxidase and catalase, are under investigation to specifically target the tumor microenvironment. Combined therapeutic strategies: dual co-targeting of PI3K/AKT pathway with metabolic enzymes and immunotherapy With the emergence of tumor drug resistance, research on dual-targeted therapies has gained significant momentum in recent years. Notably, emerging evidence has demonstrated that combining PI3K inhibitors with targeted therapies demonstrates remarkable synergistic effects in cancer treatment. For instance, the combination of the PI3K inhibitor copanlisib with metformin (an AMPK activator) significantly suppressed tumor cell viability, spheroid formation, and metastatic potential [40]. Likewise, the combination of the PI3K inhibitor omipalisib with a D-3-phosphoglycerate dehydrogenase inhibitor can block the serine synthetic metabolic compensation pathway in drug-resistant acute myeloid leukemia cells, thereby markedly reducing cell viability and prolonging the survival of tumor-bearing mice [60]. In addition, the combination of the PI3K inhibitor alpelisib with a CD36 inhibitor can specifically block the exogenous fatty acid uptake compensation pathway in PTEN-deficient breast cancer cells, substantially enhancing the efficiency of tumor cell proliferation inhibition [61]. Furthermore, the combination of PI3K/AKT inhibitor Rigosertib with MEK inhibitor Trametinib and anti-PD-1 antibody synergistically inhibits the RAS/MEK/PI3K pathway, reduces CD11b+ Breg expansion to release suppression of CD8+ T cells, and effectively overcomes PD-1 resistance in NRAS-mutant melanoma [62]. These findings conclusively demonstrate that combination regimens of "PI3K inhibitors plus metabolic enzyme inhibitors" and "PI3K inhibitors plus immunotherapy" achieve precise targeting of tumor cells through distinct mechanisms. This provides crucial theoretical foundations and data support for clinical translation in both hematologic malignancies and solid tumors. Notably, while both hematologic and solid tumors rely on PI3K/AKT-driven metabolic reprogramming, hematologic malignancies exhibit unique features, such as greater dependence on glycolysis and altered mitochondrial function. These differences should be considered when developing targeted therapies for these cancers. Conclusions and prospects In conclusion, the PI3K/AKT axis plays a central role in cancer metabolic reprogramming. By precisely regulating key glycolytic metabolic enzymes (e.g., hexokinase, pyruvate kinase, phosphofructokinase, aldolase, lactate dehydrogenase) and related signaling molecules, it profoundly influences the metabolic phenotype of cancer cells. Rate-limiting glycolytic enzymes are subject to direct and indirect modulation by the PI3K/AKT signaling axis. Through alterations in their catalytic activity and expression levels, these enzymes collectively drive hallmark metabolic features of cancer cells, such as the Warburg effect. Rather than acting as a simple switch, this signaling axis executes precise control by modulating the subcellular distribution of key enzymes—such as the mitochondrial association of HK2 and the nuclear translocation of PKM2. These modifications not only drive the classical Warburg effect but also trigger "moonlighting" functions of metabolic enzymes that promote cell survival and immune evasion. Furthermore, the crosstalk between PI3K/AKT and the AMPK sensor ensures that glucose flux is strategically shunted into the PPP and biosynthetic processes to maintain redox balance. Through remodeling glycolytic metabolism, the PI3K/AKT axis further provides cancer cells with sufficient energy supply, essential biosynthetic raw materials, and effective antioxidant protection. Beyond solid tumors, we also emphasize the necessity of considering the unique features of hematological malignancies. Collectively, these molecular mechanism insights demonstrate that targeting the PI3K/AKT-centered metabolic regulatory network is a promising and sophisticated strategy for future precision cancer therapy. Abnormal AKT signalling has extensive biological significance in cancer. It not only promotes cancer development but also affects the response to treatment of cancer. An in-depth understanding of the mechanism of action between the PI3K/AKT axis and these metabolic enzymes can provide more potential targets for targeted cancer therapy [63]. As of now, the FDA has approved five PI3K inhibitors: copanlisib, idelalisib, umbralisib, duvelisib, and alpelisib. Several AKT inhibitors — such as MK-2206, AZD5363 (capivasertib), and GDC-0068 (ipatasertib) — are currently being evaluated in Phase I/II clinical trials [52,64]. Notably, there is no AKT inhibitor approved by the FDA yet, and safety concerns have limited some development. However, there are still many other challenges at present. For example, tumor cell metabolism is highly heterogeneous. Different tumors or even different cell subpopulations within the same tumor have different degrees of dependence on the PI3K/AKT axis regulated glucose metabolic pathway. Achieving precise targeted therapy is an urgent problem that needs to be solved. In addition, there are complex interactions between the PI3K/AKT axis and other signaling pathways and metabolic pathways. Single-target therapy is prone to cause drug resistance and may also reduce radiosensitivity [65]. Moreover, some therapeutic drugs have adverse reactions, such as weight loss, liver and kidney function damage, hyperglycemia, insulin resistance, etc [19,66,67]. Future research should further explore the fine molecular mechanisms of the PI3K/AKT axis and tumor metabolic regulation. By combining multi-omics technologies and advanced bioinformatics analysis methods, in-depth analysis of tumor metabolic heterogeneity should be carried out, and combination therapy strategies targeting the PI3K/AKT axis and its related metabolic enzymes should be developed, which is expected to bring new breakthrough in tumor treatment. Abbreviation abbreviationdefinitionabbreviationdefinitionPPPpentose phosphate pathwayOXPHOSoxidative phosphorylationHKhexokinasePKpyruvate kinasePFKphosphofructokinaseLDHlactate dehydrogenaseRTKsreceptor tyrosine kinasesPIP2phosphatidylinositol (4,5)-bisphosphatePIP3phosphatidylinositol (3,4,5)-trisphosphatePDK1phosphoinositide-dependent kinase 1mTORCmechanistic target of rapamycin complexPP2Aphosphatase 2AGLUTglucose transporterPFKFBbifunctional enzyme family 6-phosphofructo-2-kinasACLYATP-citrate lyaseF-2,6-BPfructose-2,6-bisphosphateAMPKAMP-activated protein kinaseG6PDGlucose-6-Phosphate Dehydrogenase abbreviationdefinitionabbreviationdefinitionPPPpentose phosphate pathwayOXPHOSoxidative phosphorylationHKhexokinasePKpyruvate kinasePFKphosphofructokinaseLDHlactate dehydrogenaseRTKsreceptor tyrosine kinasesPIP2phosphatidylinositol (4,5)-bisphosphatePIP3phosphatidylinositol (3,4,5)-trisphosphatePDK1phosphoinositide-dependent kinase 1mTORCmechanistic target of rapamycin complexPP2Aphosphatase 2AGLUTglucose transporterPFKFBbifunctional enzyme family 6-phosphofructo-2-kinasACLYATP-citrate lyaseF-2,6-BPfructose-2,6-bisphosphateAMPKAMP-activated protein kinaseG6PDGlucose-6-Phosphate Dehydrogenase Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Availability of data and materials All data and materials supporting the conclusions of this review are derived from previously published studies, which have been cited in the reference list. The original literature can be accessed through public academic databases (e.g., PubMed) using the provided citations. No new datasets or unique materials were generated in this review. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. CRediT authorship contribution statement Sufen Cheng: Writing – original draft. Qi Jiang: Investigation. Hua Huang: Investigation. Hongyan Tong: Supervision. Mixue Xie: Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.